Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat; a phase 2 consortium/stand Up 2 cancer study

Oncotarget

Volumn 8, Issue 21, 2017, Pages 35326-35338

  Azad, Nilofer S ^a   El Khoueiry, Anthony ^b   Yin, Jun ^c   Oberg, Ann L ^c   Flynn, Patrick ^d   Adkins, Douglas ^e   Sharma, Anup ^a   Weisenberger, Daniel J ^b   Brown, Thomas ^a   Medvari, Prakriti ^a   Jones, Peter A ^f   Easwaran, Hariharan ^a   Kamel, Ihab ^a   Bahary, Nathan ^g   Kim, George ^h   Picus, Joel ^e   Pitot, Henry C ^c   Erlichman, Charles ^c   Donehower, Ross ^a   Shen, Hui ^f   Laird, Peter W ^f   Piekarz, Richard ^e   Baylin, Stephen ⁱ   Ahuja, Nita ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d Metro Minnesota CCOP   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f VAN ANDEL RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h MAYO CLINIC   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Colorectal cancer; DNA methyltransferases inhibitors; Epigenetics; Histone deacetylase inhibitors

Indexed keywords

AZACITIDINE; ENTINOSTAT; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ACIDOSIS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLORECTAL CANCER CELL LINE; CONSTIPATION; DEHYDRATION; DEMETHYLATION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPIGENETICS; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IN VIVO STUDY; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; URINARY TRACT OBSTRUCTION; VOMITING; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL TUMOR; DNA METHYLATION; DRUG ADMINISTRATION; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HCT 116 CELL LINE; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BENZAMIDES; CELL LINE, TUMOR; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA METHYLATION; DRUG ADMINISTRATION SCHEDULE; EPIGENESIS, GENETIC; FEMALE; HCT116 CELLS; HUMANS; MALE; MIDDLE AGED; PYRIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85019645055     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15108     Document Type: Article

References (41)

1. Herman JG, Ballin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349:2042-54
2. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul;1:686-92
3. Hiltunen MO, Alhonen L, Koistinaho J, Myöhänen S, Pääkkönen M, Marin S, Kosma VM, Jänne J. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer. 1997 Mar 17;70:644-8
4. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 2004 Feb 1;64:883-8
5. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repairdefective human tumor cell lines. Cancer Res. 1997 Mar 1;57:808-11
6. Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glöckner SC, de Freitas Calmon M, Hooker CM, Funes JM, Boshoff C, Smits KM, van Engeland M, et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Can Res 2011;17:1535-45
7. Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007 Sep;3:1709-23
8. Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA,Kleeberger W, de Bruïne AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, Stockbrügger RW, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009 Jun 1;69:4691-9
9. Eads CA, Nickel AE, Laird PW. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res. 2002 Mar 1;62:1296-9
10. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999 Jul 20;96:8681-6
11. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006 Jul;38:787-93
12. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001 Dec;1:194-202
13. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, et al. Phase II multiinstitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27:5410-7
14. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10;28:4485-91
15. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10:223-32
16. Karpf BC, Moore TO, Ririe DA Jones. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2-deoxycytidine Mol. Pharmacol., 59 (2001), pp. 751-757
17. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B Mol. Cell. Biol., 28 (2008), pp. 752-771
18. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999 Jan;21:103-7
19. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011 Dec;1:598-607
20. Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res. 2009 Oct 1;15:6241-9
21. Connolly RM, Jankowitz RC, Zahnow CA, Zhang Z, Rudek MA, Slater S, Powers P, Jeter S, Brufsky A, Piekarz R, Herman JG, Ahuja N, Somlo G, et al. Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Advanced Breast Cancer. ASCO 2014 (Abs 569)
22. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006 Jun 15;66:6361-9
23. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20;24:3895-903
24. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:587-98. doi:10.18632/oncotarget.1782
25. Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD, Oganesian A, Taverna P, Belinsky SA. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int J Cancer. 2014 Nov 1;135:2223-31
26. Berg M, Nordgaard O, Kørner H, Oltedal S, Smaaland R, Søreide JA, Søreide K. Molecular subtypes in stage II-III colon cancer defined by genomic instability: early recurrence-risk associated with a high copy-number variation and loss of RUNX3 and CDKN2A. PLoS One. 2015 Apr 16;10:e0122391
27. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372:2509-20
28. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloidderived cells. Proc Natl Acad Sci U S A. 2014 Aug 12;111:11774-9
29. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012 May 1;72:2197-205
30. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebocontrolled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013 Jun 10;31:2128-35
31. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol. 2013 May;10:256-66
32. Lee V, Wang J, El Khoueiry A, Verheul H, Gootjes E, Sharma A, Kerner Z, Jones P, Baylin S, Lilly E, Ahuja N, Brown T, Azad NS. A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients. Abstract CT017. AACR Annual Meeting 2016. New Orleans, LA
33. O'Dwyer PJ, Piha-Paul SA, French C, Harward S, Ferron-Brady G, Wu Y, Barbash O, Wyce A, Annan M, Horner T, Parr NJ, Prinja RK, Carpenter C, et al. GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II openlabel single-agent study in patients with NUT midline carcinoma (NMC) and other cancers. Abstract CT014. AACR Annual Meeting 2016. New Orleans, LA
34. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, et al. Transient low doses of DNAdemethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012 Mar 20;21:430-46
35. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specificPCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996 Sep 3;93:9821-6
36. Dhir M, Yachida S, Van Neste L, Glöckner SC, Jeschke J, Pappou EP, Montgomery EA, Herman JG, Baylin SB, Iacobuzio-Donahue C, Ahuja N. Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. Int J Cancer. 2011 Oct 15;129:1889-98
37. Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins DN, Ahuja N, Baylin SB. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 2008 Apr 15;68:2764-72. doi: 10.1158/0008-5472.CAN-07-6349. Erratum in: Cancer Res. 2008 Jul 15;68:6030
38. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/
39. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005 May 1;21:2067-75
40. Goeman JJ, Solari A. Multiple hypothesis testing in genomics. Stat Med. 2014 May 20;33:1946-78
41. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences (PNAS) 2003; 100:9440-5